Metabolic Mind
Psychiatrist Shares His Experience With GLP1 Weight Loss Drugs with Dr Rodrigo Mansuer
Dec 4, 2023
Dr. Rodrigo Mansur, a University of Toronto psychiatrist, discusses the use of GLP1 weight loss drugs in psychiatry, exploring their potential to target symptoms of depression and anxiety. He highlights the research behind these medications and the importance of monitoring for adverse effects. The podcast delves into the connection between metabolic and mental health, emphasizing the need for careful consideration when using these drugs in psychiatric populations.
20:57
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP1 agonist weight loss drugs like Wegovy and Ozempic show promise in targeting psychiatric symptoms beyond weight management.
- Dr. Rodrigo Mansur's research suggests GLP1 agonists may improve mood, cognitive function, and memory in psychiatric patients.
Deep dives
Exploring the Use of GLP1 Receptor Agonist Medications in Psychiatric Populations
The podcast delves into the controversial topic of utilizing GLP1 receptor agonist medications such as Wagovi and Ozempic in a specific psychiatric population. While these medications have shown potential benefits for weight loss and treating psychiatric symptoms, there are concerns regarding their side effects, including issues like increased suicidal ideation and stomach paralysis. Dr. Rodrigo Mansour, a staff psychiatrist and researcher, is actively studying the effects of these medications on psychiatric symptoms to determine the balance of their usage.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
